Minocin Mr (Minocycline Hydrochloride)

Minocycline binds to the 30S ribosomal subunit of susceptible bacteria, preventing the addition of aminoacyl‑tRNA to the growing peptide chain. This blocks protein synthesis, resulting in a bacteriostatic effect that limits bacterial growth.

The specific dose and dosing schedule of Minocin MR are determined by the prescribing clinician based on the infection type, severity, patient age, renal and hepatic function, and other individual factors.

Minocin MR is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It is generally avoided in pregnancy and should be used only if the potential benefit justifies the risk. Use while breastfeeding is also discouraged because the drug is excreted in milk.

To request Minocin MR, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Minocin MR offers an extended‑release formulation that provides once‑daily dosing, which can improve adherence compared with immediate‑release tetracyclines that often require multiple daily doses. Its spectrum of activity is similar to other tetracyclines, but the pharmacokinetic profile may differ.

Store Minocin MR tablets at room temperature, below 25 °C, in the original packaging. Keep the container tightly closed, protect from moisture and direct sunlight to maintain tablet integrity.

Minocin MR is taken orally, usually with a full glass of water. The extended‑release tablet should be swallowed whole and not crushed, chewed, or split, to preserve its designed release characteristics.

Serious risks include drug‑induced lupus, Stevens‑Johnson syndrome, severe hypersensitivity reactions, hepatic toxicity, and pseudotumor cerebri. Patients should be instructed to seek immediate medical attention if they develop rash, fever, severe headache, visual changes, or signs of liver dysfunction.

Minocin MR should be avoided in pregnant women, nursing mothers, children under eight years of age, and patients with known hypersensitivity to minocycline or other tetracycline antibiotics. Caution is also advised for individuals with severe renal or hepatic impairment.